Finerenone is a prescription medicine that can help protect the kidneys and heart in adults with diabetic kidney disease. It is usually added to other treatments. It may reduce the chance of worsening kidney problems and certain heart events, but it does not cure kidney disease or replace diabetes care. Doctors check kidney function and blood potassium before and during treatment because potassium can become too high.
Diabetic kidney disease develops when diabetes contributes to damage in the kidneys over time. Finerenone offers an additional way to help reduce the risk of kidney disease progression and cardiovascular complications, particularly in people who continue to have excess protein in their urine despite standard treatment.
How does finerenone help protect the kidneys?
Finerenone belongs to a group of medicines called nonsteroidal mineralocorticoid receptor antagonists. It blocks mineralocorticoid receptors involved in processes that can contribute to inflammation, scarring, and damage in the kidneys and cardiovascular system. Its effects can help reduce albumin in the urine and lower the risk of certain kidney and heart complications.
Albumin is a protein that normally remains mainly in the bloodstream. When kidney filters become damaged, some albumin can leak into the urine. Persistent albuminuria, meaning higher-than-expected albumin in urine, can be a sign of kidney damage and is associated with a greater risk of kidney disease progression.
Finerenone is not a blood sugar-lowering medicine. Its role is to address some of the kidney and cardiovascular risks that can remain even when a person is already receiving treatment for diabetes, blood pressure, and kidney disease.
Who may benefit from finerenone?
Finerenone is particularly relevant to adults with chronic kidney disease associated with type 2 diabetes who continue to have albuminuria despite treatment with an ACE inhibitor or an angiotensin receptor blocker (ARB), taken at the highest tolerated dose when appropriate. These medicines help protect the kidneys, while finerenone can provide an additional protective effect.
The American Diabetes Association's Standards of Care in Diabetes recommends a nonsteroidal mineralocorticoid receptor antagonist with demonstrated clinical benefits for people with chronic kidney disease and albuminuria when estimated kidney function is adequate for treatment and potassium can be monitored.
Before prescribing finerenone, a healthcare professional considers several factors:
- Whether chronic kidney disease is associated with diabetes and whether urine albumin remains elevated.
- The estimated glomerular filtration rate (eGFR), a blood-test-based estimate of how well the kidneys filter waste.
- The blood potassium level and whether other medicines could increase it.
- Current kidney-protective treatment, blood pressure, other health conditions, and the risk of cardiovascular complications.
In the United States, the current prescribing information also includes an indication for adults with chronic kidney disease associated with type 1 diabetes, focused on reducing the urine albumin-to-creatinine ratio, with the expected benefit of reducing kidney disease progression. The evidence for reducing major kidney and cardiovascular events discussed below comes primarily from studies in adults with type 2 diabetes. Approved uses and recommendations may differ between countries.
What do clinical studies show about finerenone?
Clinical trials have examined whether finerenone can reduce important complications in people with type 2 diabetes and chronic kidney disease. In the FIDELIO-DKD trial, published in the New England Journal of Medicine, participants receiving finerenone had a lower risk of a combined kidney outcome than those receiving a placebo alongside standard care. The outcome included kidney failure, a sustained decline in kidney function, or death from kidney-related causes. During a median follow-up of 2.6 years, the outcome occurred in 17.8% of the finerenone group and 21.1% of the placebo group.
A broader analysis called FIDELITY combined results from two large clinical trials involving more than 13,000 people with type 2 diabetes and chronic kidney disease. The European Heart Journal's published FIDELITY analysis found that finerenone reduced the relative risk of the combined kidney outcome by about 23% and the combined cardiovascular outcome by about 14% compared with placebo. The cardiovascular outcome included cardiovascular death, nonfatal heart attack, nonfatal stroke, or hospitalization for heart failure.
These findings support finerenone as an additional treatment for appropriately selected adults with diabetic kidney disease. They do not mean that every person will experience the same benefit or that the medicine prevents all kidney or heart complications. The trials evaluated finerenone alongside standard treatment, rather than as a replacement for established kidney-protective care.
How is finerenone prescribed?
Finerenone is taken by mouth, usually once daily. The dose depends on kidney function, blood potassium, and the applicable prescribing guidance. In the United States, the prescribing information for chronic kidney disease associated with type 2 diabetes specifies a usual target dose of 20 mg daily, with the starting dose determined by eGFR.
Under the U.S. prescribing information, adults with an eGFR of at least 60 mL/min/1.73 m² generally start at 20 mg daily. Those with an eGFR of 25 to less than 60 generally start at 10 mg daily. Starting treatment is not recommended when eGFR is below 25, and treatment must not be initiated if blood potassium is above 5.0 mEq/L. The dose may be adjusted after reviewing blood-test results. These details are based on U.S. labeling and may differ from local guidance.
The U.S. National Library of Medicine's DailyMed prescribing information recommends checking blood potassium and eGFR before starting finerenone, again about four weeks after initiation, and about four weeks after a dose adjustment. Further checks are needed throughout treatment, with closer monitoring when a person's medicines, kidney function, or potassium-related risks make it necessary.
Patients should take finerenone exactly as prescribed and should not increase, reduce, restart, or stop it on their own. If a dose is missed, the appropriate action is to follow the prescribing instructions or contact a pharmacist or healthcare professional rather than taking extra tablets to make up for it.
Why must potassium and kidney function be monitored?
The main safety concern with finerenone is hyperkalemia, which means a higher-than-expected level of potassium in the blood. Potassium helps nerves and muscles function normally, including the heart muscle, but too much can disturb the heart's electrical activity. Hyperkalemia may not cause obvious symptoms, so blood tests are important even when a person feels well.
The chance of developing high potassium can increase when kidney function is reduced, when potassium is already near the upper end of the acceptable range, or when other medicines affect potassium levels. Monitoring helps the prescribing professional decide whether to continue the current dose, adjust it, temporarily withhold treatment, or consider restarting it later.
Kidney function is also monitored because eGFR can change during treatment. The clinician considers the size and pattern of any change alongside potassium results, blood pressure, hydration, other medicines, and the person's overall condition. A change in one test result does not automatically determine whether treatment should continue.
What are the possible side effects of finerenone?
Hyperkalemia is one of the most important adverse effects to understand. In clinical studies, it was more common with finerenone than with placebo, and in some participants it led to treatment interruption or discontinuation. Regular blood tests are intended to identify this problem and guide safe treatment.
Other reported adverse effects can include low blood pressure and low blood sodium. Their importance depends on the individual's health and other medicines. Tell the treating professional about new symptoms or changes in how you feel, especially marked weakness, unusual heart palpitations, fainting, or significant dizziness. These experiences can have different causes, but may require prompt medical assessment.
Seek urgent medical care for fainting, severe weakness, chest discomfort, or a sensation of a rapid or irregular heartbeat, particularly if a clinician has raised concern about high potassium. Do not wait for symptoms to develop before attending scheduled blood tests, because potassium changes can occur without noticeable warning signs.
Which medicines and supplements can interact with finerenone?
Some medicines can increase finerenone levels or make high potassium more likely. Strong CYP3A4 inhibitors, a group of medicines that affect how finerenone is broken down, are contraindicated in the current U.S. prescribing information. Other medicines that influence CYP3A4 may require avoidance, additional monitoring, or a treatment adjustment.
Before treatment begins, provide the prescriber or pharmacist with a complete list of prescription medicines, nonprescription products, and supplements. Include other drugs that may raise potassium and any potassium supplements or potassium-containing salt substitutes. Do not stop prescribed medicines or make dietary changes intended to manage potassium without discussing the issue with the healthcare team.
Can finerenone be taken with other kidney-protective medicines?
Finerenone is generally considered an additional treatment, not a substitute for other recommended care. For people with type 2 diabetes and chronic kidney disease, treatment may include an ACE inhibitor or ARB, an SGLT2 inhibitor when appropriate, and measures to manage blood glucose and blood pressure. The exact combination depends on kidney function, cardiovascular history, potassium levels, tolerability, and other clinical factors.
The KDIGO 2024 Clinical Practice Guideline for Chronic Kidney Disease supports considering a nonsteroidal mineralocorticoid receptor antagonist with proven kidney or cardiovascular benefits in adults with type 2 diabetes, persistent albuminuria, adequate eGFR, and normal potassium despite a maximum tolerated renin-angiotensin system inhibitor. The guideline also notes that a medicine in this class may be added to both renin-angiotensin system treatment and an SGLT2 inhibitor when appropriate.
Using several kidney-protective treatments together requires coordinated follow-up. A healthcare professional can review how each medicine contributes to kidney or heart protection, assess possible interactions, and plan the necessary blood tests. Finerenone should not be viewed as a replacement for diabetes management, blood pressure treatment, or regular assessment of kidney health.
Who should discuss finerenone carefully with a healthcare professional?
Finerenone may not be suitable for everyone. In addition to potassium and kidney-function concerns, the current U.S. label lists adrenal insufficiency and hypersensitivity to the medicine as contraindications, along with the use of strong CYP3A4 inhibitors. Other medicines and health conditions may also affect the treatment decision.
The established diabetic kidney disease indications in the U.S. prescribing information are for adults. Treatment in children should not be assumed to have the same benefits or safety profile. People who are pregnant, planning pregnancy, or breastfeeding should discuss their circumstances with the prescribing clinician because medication recommendations may differ during these periods.
Finerenone is most useful when its potential benefits, laboratory monitoring requirements, and interaction risks have been considered together. A conversation with the prescribing professional can clarify whether it fits the current treatment plan and how its effects will be assessed over time.